Skip to main navigation Skip to search Skip to main content

5-Aminopyrazole-4-carboxamide-based compounds prevent the growth of Cryptosporidium parvum

  • Wenlin Huang
  • , Ryan Choi
  • , Matthew A. Hulverson
  • , Zhongsheng Zhang
  • , Molly C. McCloskey
  • , Deborah A. Schaefer
  • , Grant R. Whitman
  • , Lynn K. Barrett
  • , Rama Subba Rao Vidadala
  • , Michael W. Riggs
  • , Dustin J. Maly
  • , Wesley C. Van Voorhis
  • , Kayode K. Ojo
  • , Erkang Fan

Research output: Contribution to journalArticlepeer-review

Abstract

Cryptosporidium parvum calcium-dependent protein kinase 1 (CpCDPK1) is a promising target for drug development against cryptosporidiosis. We report a series of low-nanomolar CpCDPK1 5-aminopyrazole-4-carboxamide (AC) scaffold inhibitors that also potently inhibit C. parvum growth in vitro. Correlation between anti-CpCDPK1 and C. parvum growth inhibition, as previously reported for pyrazolopyrimidines, was not apparent. Nonetheless, lead AC compounds exhibited a substantial reduction of parasite burden in the neonatal mouse cryptosporidiosis model when dosed at 25 mg/kg.

Original languageEnglish (US)
Article numbere00020
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number8
DOIs
StatePublished - Aug 2017

Keywords

  • 5-aminopyrazole-4-carboxamide
  • Bumped kinase inhibitors
  • Cryptosporidium parvum

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of '5-Aminopyrazole-4-carboxamide-based compounds prevent the growth of Cryptosporidium parvum'. Together they form a unique fingerprint.

Cite this